Literature DB >> 1361959

A comprehensive macrophage-T-lymphocyte theory of schizophrenia.

R S Smith.   

Abstract

Chronic macrophage activation with subsequent failure of activated macrophages to properly control T-lymphocyte secretion of interleukin-2 and interleukin-2 receptors is proposed as the basic biological mechanism of schizophrenia. Fundamental to this theory are the clinical observations on interleukin-2 provoking the active phase symptoms of schizophrenia in psychiatrically normal human volunteers and macrophage cytokines producing the prodromal and residual phase symptoms. This theory provides a completely new and unified mechanisms for the antipsychotic action of typical and atypical neuroleptics, bromocriptine, naloxone and DMSO. Furthermore, this hypothesis reveals why the dopamine theory of schizophrenia was a false lead. The effects of prolactin, estrogens and androgens are consistent with the model. Age of onset, male/female incidence, course of the disease from prodromal to active to residual phase, the protection afforded by rheumatoid arthritis and the close relationship between depression and schizophrenia can be explained by this theory. The gastrointestinal tract is suggested as the preferred site to investigate for the cause of the immune activation in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1361959     DOI: 10.1016/0306-9877(92)90117-u

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  21 in total

1.  A Study of TNF Pathway Activation in Schizophrenia and Bipolar Disorder in Plasma and Brain Tissue.

Authors:  Eva Zsuzsanna Hoseth; Thor Ueland; Ingrid Dieset; Rebecca Birnbaum; Joo Heon Shin; Joel Edward Kleinman; Thomas Michael Hyde; Ragni Helene Mørch; Sigrun Hope; Tove Lekva; Aurelija Judita Abraityte; Annika E Michelsen; Ingrid Melle; Lars Tjelta Westlye; Torill Ueland; Srdjan Djurovic; Pål Aukrust; Daniel R Weinberger; Ole Andreas Andreassen
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

Review 2.  Is there a role for immune-to-brain communication in schizophrenia?

Authors:  Golam M Khandaker; Robert Dantzer
Journal:  Psychopharmacology (Berl)       Date:  2015-06-04       Impact factor: 4.530

3.  Areca nut chewing is associated with common mental disorders: a population-based study.

Authors:  Tzu-Yu Lin; Huan-Cheng Chang; Kuang-Hung Hsu
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2017-11-15       Impact factor: 4.328

Review 4.  Th17 pathway-mediated immunopathogenesis of schizophrenia: mechanisms and implications.

Authors:  Monojit Debnath; Michael Berk
Journal:  Schizophr Bull       Date:  2014-04-07       Impact factor: 9.306

5.  Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia.

Authors:  N Müller; M Empl; M Riedel; M Schwarz; M Ackenheil
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

Review 6.  Adaptive Immunity in Schizophrenia: Functional Implications of T Cells in the Etiology, Course and Treatment.

Authors:  Monojit Debnath
Journal:  J Neuroimmune Pharmacol       Date:  2015-07-11       Impact factor: 4.147

Review 7.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

Review 8.  [Cytokine network in patients with schizophrenia and its significance for the pathophysiology of the illness].

Authors:  A Schuld; D Hinze-Selch; Th Pollmächer
Journal:  Nervenarzt       Date:  2004-03       Impact factor: 1.214

9.  Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression.

Authors:  M Maes; H Y Meltzer; P Buckley; E Bosmans
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1995       Impact factor: 5.270

10.  Activating transcription factor 3 and the nervous system.

Authors:  David Hunt; Gennadij Raivich; Patrick Norval Anderson
Journal:  Front Mol Neurosci       Date:  2012-02-14       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.